

Lynch Syndrome: It's more common than you think

>1/4 WITH LYNCH SYNDROME ARE MISSED BY CURRENT GENETIC TESTING GUIDELINES



Ambry Genetics and The Ohio State University research of nearly 35,000 patients, published in the [Journal of Clinical Oncology](#), expands how we think about genetic testing strategies, lifetime cancer risks, and medical management for people with Lynch syndrome.¹

WHY THIS MATTERS TO YOU

This study found that 27.3% of people with Lynch syndrome are missed by current genetic testing guidelines. Additionally, >25% of Lynch syndrome gene mutation carriers presented with breast or ovarian cancer as their first primary cancer.¹ As a result we recommend ordering a larger panel, such as CancerNext, to identify patients with mutations in *BRCA1/2*, in addition to Lynch syndrome.

BACKGROUND

Lynch syndrome (LS) is estimated to occur in 1 in 440 people², but recent research suggests this should be as high as 1 in 279 - making LS the most common hereditary cancer syndrome.³

Genetic testing for LS is increasingly performed using multigene panels; results can impact cancer risk assessment and direct medical management, often following published guidelines.⁴

Many current LS guidelines are based on studies biased toward colorectal cancer and/or endometrial cancer, and many did not analyze all LS genes.⁵⁻¹⁰ Basing LS genetic testing on a patient meeting Amsterdam criteria or Bethesda guidelines may miss as many as 72% and 27% of those with LS, respectively.⁸ Screening for LS with microsatellite instability (MSI) and/or immunohistochemistry (IHC) for the mismatch repair (MMR) proteins may miss 13-23%.⁸



34,890

People Tested for
Lynch Syndrome


POINTS FOR YOUR PRACTICE

- This study reports on the largest group of individuals tested for and diagnosed with LS through multigene panel testing
- Current genetic testing guidelines may miss more than 1 in 4 people with LS
- Some women with LS may have a hereditary breast and ovarian cancer (HBOC) clinical presentation


SIGNIFICANT FINDINGS

- *MSH6* and *PMS2* mutations were most commonly seen
- *MSH6* and *PMS2* mutation carriers were significantly more likely to just have breast cancer and only meet *BRCA1/2* NCCN® testing criteria
- Overall, 27.3% of people did not meet any current criteria for LS testing

Overall MMR and *EPCAM* Gene Distribution (n=579)



How Current Genetic Testing Guidelines Stacked Up^{4,11}
 PATIENTS WHO MET NCCN® GENETIC TESTING GUIDELINES FOR:



Learn more about our research [here](#).

REFERENCES

1. Espenschied C, et al. Multi-gene panel testing provides a new perspective on Lynch syndrome. *J Clin Oncol*. April 2017 [Epub ahead of print].
2. Chen S, et al. Prediction of germline mutations and cancer risk in the Lynch syndrome. *JAMA*. 2006 Sep 27;296(12):1479-87.
3. Win AK, et al. Prevalence and penetrance of major genes and polygenes for colorectal cancer. *Cancer Epidemiol Biomarkers Prev*. 2017 Mar;26(3):404-412.
4. National Comprehensive Cancer Network®. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)*. Genetic/Familial High-Risk Assessment: Colorectal. Version 2.2016. Accessed April 25, 2017. Available from nccn.org
5. Hampel H, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. *Cancer Res*. 2006 Aug 1;66(15):7810-7.
6. Hampel H, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. *J Clin Oncol*. 2008 Dec 10;26(35):5783-8.
7. Bonadona V, et al. Cancer risks associated with germline mutations in *MLH1*, *MSH2*, and *MSH6* genes in Lynch syndrome. *JAMA*. 2011 Jun 8;305(22):2304-10.
8. Palomaki GE, et al. EGAPP supplementary evidence review: DNA testing strategies aimed at reducing morbidity and mortality from Lynch syndrome. *Genet Med*. 2009 Jan;11(1):42-65.
9. Moreira L, et al. Identification of Lynch syndrome among patients with colorectal cancer. *JAMA*. 2012 Oct 17;308(15):1555-65.
10. Moller P, et al. Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. *Gut*. 2017 Mar;66(3):464-472.
11. National Comprehensive Cancer Network®. *NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®)*. Genetic/Familial High-Risk Assessment: Breast and Ovarian. Version 2.2017. Accessed April 25, 2017. Available from nccn.org